Pharmaceutical Sector

Discover how companies in the pharmaceutical field monitor impacts, dependencies, risks, and opportunities related to nature, biodiversity, and climate with XNatura.

3

Countries in which we operate

7

Sites monitored

46.561

Hectares monitored

2

Regenerated hectares

Trusted by more than 500 companies and 10,000 sites

findus
a2a-life-company
gardaland
heraeus
dhl
edison-next
esa
A35 Brebemi
cubico
fattoria di maiano
gest
la maliosa
parco del vesuvio
parco groane
san pellegrino
parco valle lambro
scapigliato
wpd
mondelez international
comoli ferrari
bracco
regenerative-society-foundation
phoenix-contact
aboca
credit-agricole
mutti-pomodoro
thales-alenia-space
bam
alce-nero
findus
a2a-life-company
gardaland
heraeus
dhl
edison-next
esa
A35 Brebemi
cubico
fattoria di maiano
gest
la maliosa
parco del vesuvio
parco groane
san pellegrino
parco valle lambro
scapigliato
wpd
mondelez international
comoli ferrari
bracco
regenerative-society-foundation
phoenix-contact
aboca
credit-agricole
mutti-pomodoro
thales-alenia-space
bam
alce-nero

Why monitor biodiversity in the pharmaceutical sector?

In the pharmaceutical sector, monitoring biodiversity is essential to prevent risks associated with the loss of natural habitats and climate change. Integrating biodiversity into production sites helps promote a positive relationship with the surrounding environment, supporting resilience.

Reduction of heat island effect
Enhancement of natural habitats
Promotion of innovation
Biodiversity Natural Footprint
Supply chain Natural risk
Reduction of heat island effect

Reduction of heat island effect

  • Threat
    Pharmaceutical facilities and manufacturing sites, which are often characterized by vast sealed areas and paved areas, contribute to heat buildup, creating microclimates that disrupt the natural balance.
  • Opportunities
    Implementing strategies for integrating green areas can help reduce the heat island effect and enhance local biodiversity by creating natural habitats near pharmaceutical facilities.
Protection and enhancement of natural habitats

Protection and enhancement of natural habitats

  • Threat
    Many production sites are located near vulnerable ecosystems, disrupting ecological connections and fragmenting natural habitats. This impairs the mobility of fauna and reduces the natural resources available for local flora.
  • Opportunities
    By taking measures to restore and strengthen ecological corridors, the connection between natural habitats can be improved and biodiversity enhanced.
Promotion of sustainable innovation

Promotion of sustainable innovation

  • Threat
    The dependence of pharmaceutical activities on natural resources, combined with the loss of biodiversity and habitat degradation, can undermine environmental stability and reduce the availability of raw materials needed for production.
  • Opportunities
    Investing in innovative solutions that integrate biodiversity into pharmaceutical and production sites helps protect local ecosystems, creating environments conducive to biodiversity.
Biodiversity Natural Footprint

Biodiversity Natural Footprint

  • From sourcing active ingredients in wild areas to process emissions, the pharmaceutical industry interacts with fragile ecosystems.
  • Monitoring its biodiversity footprint means evaluating every stage - from raw materials to waste - in order to identify harm-reduction measures and restoration programs. Transparent analysis highlights achievements and strengthens trust among partners and consumers.
Supply chain Natural risk

Supply chain Natural risk

  • Global supply chains can pass through areas of high ecological fragility, exposed to drought or habitat loss.
  • Mapping these risks across suppliers and transportation routes helps define diversification plans and adaptation measures, such as alternative suppliers or strategic stockpiles. This approach protects production continuity while supporting ecosystem health.

Why choose XNatura for the pharmaceutical sector?

XNatura offers pharmaceutical companies an advanced platform for environmental monitoring, providing reliable data and analytical tools to manage the impact on biodiversity.

Traceable and transparent data
Vertical industry benchmarks
Single tool for environmental data management
Regulatory compliance

XNatura provides accurate and transparent data by integrating satellite technologies, artificial intelligence, and IoT sensors. This information makes it possible to monitor impacts on nature, biodiversity, and climate and optimize mitigation strategies.

The case studies of the pharmaceutical sector

Explore our case studies and discover how companies in the pharmaceutical sector use XNatura, integrating biodiversity monitoring into their activities.

Measurable impact and long-term benefits

XNatura provides companies with scientific data and advanced tools to assess risks, impacts, dependencies and opportunities, define biodiversity strategies and ensure regulatory compliance.

Management of environmental risks and impactsMonitoring the environmental impacts and dependencies of pharmaceutical activities enables early identification of risks and opportunities related to biodiversity, nature, and climate and improves business resilience.Monitoring the environmental impacts and dependencies of pharmaceutical activities enables early identification of risks and opportunities related to biodiversity, nature, and climate and improves business resilience.

Choose our services

XNatura’s assessment suite uses recognized protocols to rank your sites’ nature, biodiversity, and climate priority.

Site PrioritizationIdentification of priority sites and assets on Biodiversity, Climate, and Nature
Includes
Encore Impact and Dependencies Matrix
Water & Climate Risk
State of Biodiversity
Generic Climate Risk
Landslide and Erosion Risk
Key Biodiversity Areas
Urbanization and Demography
Double MaterialityIdentify your impacts and risks
IncludesSite Prioritizationplus
Impact Analysis E1-E5
Risk Analysis E1-E5
Double Materiality Matrix
Stakeholder Engagement Analysis
Materiality Benchmarking
Value Chain Analysis
Biodiversity & Nature StrategyTransition & Strategy plan for biodiversity and nature compliant with TNFD, SBTN, & GBF
IncludesDouble Materialityplus
Target Identification & Definition
Business Plan E-Strategy
Scenario Analysis

Do you want a personalized plan

Want to monitor risks, impacts, dependencies, and opportunities on nature, biodiversity, and climate in one platform? Get started today with XNatura.

Companies that have chosen XNatura

Choosing XNatura means adopting an innovative, data-driven approach. This ensures transparency and full compliance with environmental regulations.

background
Contact us for more information

I accept that my personal data will be processed to respond to my request, as indicated in the Privacy Policy. (mandatory)

I consent to receive marketing communications and promotional material from 3Bee, as indicated in the Privacy Policy.

Monitoring biodiversity in the pharmaceutical sector is essential for understanding the impacts and dependencies of production activities on ecosystems and improving the management of natural resources. Integrating biodiversity into production sites helps promote a positive relationship with the surrounding environment, supporting the resilience and adaptability of structures.